Newsroom

March 2020

• Statement Mar 27, 2020

  Novartis announces further steps to protect and support its associates during the COVID-19 Pandemic

• 
  Story Mar 27, 2020 Discovery

  Visualizing molecular glues

  Molecular glues are a new type of medicine inspired by nature’s matchmakers.

• Ad hoc release Mar 27, 2020

  Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum

  EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data1 If approved, Cosentyx would…
• Ad hoc release Mar 27, 2020

  AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)

  Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with spinal muscular atrophy (SMA) and…
• 
  Story Mar 26, 2020 Patient Perspectives

  Caring for someone with heart failure

  Caring for someone with heart failure can be both demanding and rewarding. Learn about the impact of being a carer and the support that carers need.

• Press release Mar 26, 2020

  Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation

  Collaboration to address product development and scale up challenges posed by current pandemic Basel, March 26, 2020 — Today, Novartis and a consortium of life sciences companies announced an…
• Press release Mar 24, 2020

  Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing

  Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma® (onasemnogene abeparvovec-xioi) soon after birth achieved age-appropriate motor milestones In addition to…
• Press release Mar 24, 2020

  AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2

  SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12,…
• Press release Mar 20, 2020

  Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response

  Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis Sandoz division will pursue appropriate regulatory…
• Ad hoc release Mar 19, 2020

  Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)

  Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, is approved for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at…
• Press release Mar 18, 2020

  Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy

  Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk…
• Press release Mar 17, 2020

  Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities

  Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak  Novartis to join collaborative R…